|Bid||44.65 x 400|
|Ask||44.80 x 200|
|Day's Range||44.10 - 45.30|
|52 Week Range||29.81 - 58.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.07|
Pacira (PCRX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PARSIPPANY, N.J., Dec. 08, 2017-- Pacira Pharmaceuticals, Inc. today announced that the company is scheduled to present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference at ...
A Relative Strength Rating upgrade for Pacira Pharmaceuticals shows improving technical performance. Will it continue?
Pacira Pharmaceuticals Inc. said Thursday it has named Scott Braunstein as chief operation officer and Richard Scranton as chief scientific officer. Scranton will head research, while leading communications ...
PARSIPPANY, N.J., Dec. 07, 2017-- Pacira Pharmaceuticals, Inc. today announced that Scott Braunstein, MD, has been named Chief Operating Officer and Richard Scranton, MD, has been named Chief Scientific ...
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Praxair, ...
BOCA RATON, Fla., Nov. 29, 2017 /PRNewswire/ -- Cancer Treatment Centers of America® (CTCA), a national network of five hospitals, and Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on opioid alternatives, today announced a new collaboration dedicated to reducing the risk of opioid dependence among cancer patients. The goal of the Opioid Risk Reduction Initiative—an educational effort focused on responsible use and increased awareness of opioid alternatives—is to improve the cancer patient experience through expanded pain management options.
A Relative Strength Rating upgrade for Pacira Pharmaceuticals shows improving technical performance.
Short interest is moderate for PCRX with between 5 and 10% of shares outstanding currently on loan. The net inflows of $2.69 billion over the last one-month into ETFs that hold PCRX are not among the highest of the last year and have been slowing.
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.
Pacira nose-dived Tuesday after the FDA said an advisory committee would review the benefits of its drug Exparel as a regional anesthetic.
PARSIPPANY, N.J., Nov. 14, 2017-- Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has notified the company that its supplemental New Drug Application for EXPAREL ...
PARSIPPANY, N.J., Nov. 09, 2017-- Pacira Pharmaceuticals, Inc. today announced that members of its management team are scheduled to present at the following two healthcare conferences:. Jefferies 2017 ...
Despite a mixed third-quarter report, Pacira topped Wall Street's expectations where it counts.
On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 19 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 11 cents per share. The results ...
Pacira Pharmaceuticals, Inc. today announced consolidated financial results for the third quarter ended September 30, 2017."We continue to make important progress during 2017 as we advance our strategy ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Pacira Pharmaceuticals, Inc. a score of 59. Our analysis is based on comparing Pacira Pharmaceuticals, Inc. with the following peers – DURECT Corporation, Recro Pharma, Inc., Flexion Therapeutics, Inc., Heron Therapeutics Inc, BioDelivery Sciences International, Inc., Cara Therapeutics Inc, Acura Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., Depomed, Inc. ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pacira Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
PARSIPPANY, N.J., Oct. 31, 2017-- Pacira Pharmaceuticals, Inc. today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday November 8, 2017. ...